Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSRT combined with RC48 for HER2-positive breast cancer with brain metastases
ChiCTR2300070487Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in breast cancer and brain metastases, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Intracranial objective response rate. Planned start May 2023; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR2300070487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070487.